Hot off the heels of our COVID-19 report, BIVDA have now released a new genomics whitepaper – marking our second report launch in as many weeks. The genomics whitepaper titled, ‘Leveraging advanced diagnostics to realise the UK’s potential in genomics: A new whitepaper’, examines the UK genomics landscape, with a focus on patient access to genomic testing.
The independent report, undertaken by Charles River Associates under commission for BIVDA, has identified a series of reasons for limited access to genomic testing for UK patients, while also recognising opportunities to improve the current situation.
Regulatory issues, a lack of centralised guidance on the applicability of different funding pathways and underdeveloped infrastructure to increase testing capacity are all persistent issues which currently hamper the UK genomics climate.
Establishing critical partnerships across both the public and private sector, alongside the enactment of policy change, can begin to erode these barriers and improve the adoption of, and access to, genomic testing for UK patients.
We are delighted by the release of the report and thank all members of the Genomics Working Party and other contributors for helping to create such a comprehensive paper.
You can read the paper in full here.
